Leerink Partners analyst Stephanie Davis reiterated a Buy rating on R1 RCM (NASDAQ:RCM) on Thursday, setting a price target of $35, which is approximately 45.47% above the present share price of $24.06.
Davis expects R1 RCM to post earnings per share (EPS) of $0.06 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in R1 RCM, with an average price target of $29.6.
The analysts price targets range from a high of $35 to a low of $28.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $379.7 million and a net profit of $42.5 million. The company's market cap is $6.68 billion.
According to TipRanks.com, Leerink Partners analyst Stephanie Davis is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.9% and a 48.39% success rate.
R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.